PCRX Pacira BioSciences, Inc.

36.48USD+0.05%Mkt Cap: 1.46B USDP/E: 39.23

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The co…

Institutional holders20 on file

Key Statistics

Company
Market Cap1.46B USD
Enterprise Value1.51B USD
Revenue (TTM)743.30M USD
Gross Profit576.66M USD
Net Income (TTM)7.03M USD
Revenue/Share18.32 USD
Last Price36.48 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees825
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)39.23
P/E (Forward)10.22
PEG0.99
EV/EBITDA12.73
EV/Revenue2.03
P/S1.96
P/B2.04
EPS (TTM)0.93 USD
EPS (Forward)3.57 USD
52W Range
18.8099% of range36.67
52W High36.67 USD
52W Low18.80 USD
Profitability
Gross Margin79.39%
Oper. Margin4.00%
EBITDA Margin15.93%
Profit Margin0.97%
ROE1.01%
ROA0.56%
ROIC1.10%
ROCE1.68%
Growth
Revenue Growth-1.60%
Earnings Growth483.30%
Cash Flow & Leverage
Operating CF151.99M USD
CapEx (TTM)15.33M USD
FCF Margin25.26%
FCF Yield12.90%
Net Debt44.70M USD
Net Debt/EBITDA0.38
Net Debt/FCF0.24
Balance Sheet
Debt/Equity0.60
Current Ratio4.68
Quick Ratio3.38
Book Value/Sh17.85 USD
Cash/Share7.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.57 USD
Upside (mean)-8.0%
Target Range25.00 USD – 36.50 USD
25.00-8.0% to mean36.50
# Analysts7
Ownership
Shares Out.39.91M
Float39.37M
Insiders1.33%
Institutions109.24%
Short Interest
Short Ratio1.4d
Short % Float12.05%
Short % Out.8.39%
Shares Short3.35M
Short (prev mo.)8.08M
Technical
SMA 5031.39 (+16.2%)
SMA 20025.73 (+41.8%)
Beta0.22
S&P 52W Chg12.08%
Avg Vol (30d)2.23M
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)83.3
MACD1.2199
MACD Signal1.5921
MACD Hist.-0.3722
BB Upper36.50 USD
BB Middle36.41 USD
BB Lower36.33 USD
BB Width0.48%
ATR (14)0.2595 USD
Vol Ratio (20d)1.75x

About Pacira BioSciences (NASDAQ: PCRX)

›

Pacira BioSciences (NASDAQ: PCRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 825 employees.

The shares were at 36.48 USD on 16 November 2026, up 70.6% over 52 weeks. Its 52-week range is 18.80 USD to 36.67 USD, and it trades at the top of that range.

At a market capitalisation of 1.46B USD, it trades at 39.2 times trailing earnings and 10.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 59% for PCRX.

Pacira BioSciences reports return on equity of 1.0%, an operating margin of 4.0% and revenue down 1.6% year over year.

Its debt exceeds its cash by 44.70M USD, a debt-to-equity ratio of 0.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 33.57 USD is 8.0% below the current price. The next earnings report is expected on 25 February 2027.